MOBILE VIEW  | 

NECROTIC ARACHNIDISM

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) Loxosceles species (over a 100 species have been described) can produce the most severe form of necrotic arachnidism. Not all necrotic spider bites are due to the brown recluse. Many other genera of spiders are known to cause minor necrotic lesions.

Specific Substances

    A) UNITED STATES
    1) Brown or Violin Spiders (Loxosceles)
    2) Giant Crab Spider (Heteropoda)
    3) Gnaphosid Spider (Drassodes species)
    4) Jumping Spiders (Phidippus)
    5) Orbweavers (Araneus, Argiope)
    6) Running Spider (Drassodes)
    7) Sac Spider (Chiracanthium)
    8) Tangleweb Weaver (Steatoda species)
    9) Tarantulas (Aphonopelma)
    10) Northwestern Brown Spider or Hobo Spider (Tegenaria agrestis)
    11) Wolf Spiders (Lycosa)
    12) References: (Wasserman, 1988; Willis, 1988; Vest, 1987)
    OUTSIDE THE UNITED STATES
    1) Acanthoscurria
    2) Avicularia
    3) Lampona (White-tailed spider)
    4) Megaphobema
    5) Pamphobeteus
    6) Phormictopus
    7) Sicarius
    8) Teraphosa
    9) Xenesthis
    10) References: (Gendron, 1990; Newlands & Atkinson, 1990; Wasserman & Anderson, 1984; Wasserman, 1988)
    GENERAL TERMS
    1) BROWN RECLUSE SPIDERS
    2) SPIDER, BROWN RECLUSE (COMMON NAME FOR LOXOSCELES RECLUSA)
    3) FIDDLEBACK SPIDER (COMMON NAME FOR LOXOSCELES RECLUSA)
    4) BROWN OR VIOLIN SPIDERS
    5) LOXOSCELES
    6) LOXOSCELES LAETA (ZOOLOGICAL NAME - SOUTH AMERICAN VARIETY)
    7) LOXOSCELES RECLUSA (ZOOLOGICAL NAME)
    8) RECLUSE SPIDER, BROWN (COMMON NAME FOR LOXOSCELES RECLUSA)
    9) RUNNING SPIDER (COMMON NAME FOR LIOCRANOIDES AND CHIRACANTHIUM SPECIES)
    10) SPIDER (BROWN)
    11) SPIDER, RUNNING (COMMON NAME FOR LIOCRANOIDES AND CHIRACANTHIUM SPECIES)
    12) SPIDER-TEGENARIA AGRESTIS
    13) SPIDER, VIOLIN (COMMON NAME FOR LOXOSCELES RECLUSA)
    14) SPIDERS (BROWN)
    15) BROWN RECLUSE SPIDER (COMMON NAME FOR LOXOSCELES RECLUSA)
    16) VIOLIN SPIDER (COMMON NAME FOR LOXOSCELES RECLUSA)
    17) SPIDERS, BROWN OR VIOLIN
    18) SPIDER, FIDDLEBACK (COMMON NAME FOR LOXOSCELES RECLUSA)

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) ORGANISM: Loxosceles spiders are distributed in discreet populations across the US, primarily in the Midwest and Southwest. Loxosceles species include: L. reclusa, L. refescens, L. lacta, L. unicolor, L. deserta, L. arizonica, and others. These spiders are often found in ground cover or in plants as well as in human dwellings. They may have a distinct violin-shaped mark on the dorsum of the cephalothorax and can be differentiated from other spiders by their set of 6 eyes (in 3 pairs) rather than the 8 eyes seen in most other spider species. It is likely that some, if not many dermonecrotic lesions attributed to spider bites are from other causes.
    B) TOXICOLOGY: The venom of Loxosceles species is composed of a number of proteins, enzymes, and nonenzymatic polypeptides. Brown recluse venom contains sphingomyelinase among other toxins and component synergism may play a part in the overall tissue response. Perhaps more important is the response of host cells to the presence of a complement-mediating foreign substance. Loxosceles venom has been shown to be a potent inducer of multiple inflammatory mediating chemokines. Venom toxins may act as proteases upon molecular constituents of plasma extracellular matrix and basement membrane constituents producing hemorrhage, delayed wound healing and renal failure, as well as the spreading of other noxious toxins.
    C) EPIDEMIOLOGY: Painful bites may be noticed immediately and the offending spider seen, but many are not appreciated at the time and a diagnosis is made in retrospect from a characteristic history and physical examination. The incidence of necrotic arachnidism is unknown; there are no definitive diagnostic tests, and it is likely that some dermonecrotic lesions are falsely attributed to spider bites. In 2008, there were over 4,000 cases of spider or unknown insect bite reported to US poison centers, of which over 1700 were coded as "Brown Recluse" or "Necrotizing, other". Eleven major outcomes were reported, but no deaths.
    D) WITH POISONING/EXPOSURE
    1) MILD TO MODERATE TOXICITY: Bites by most of the species of spiders listed above are usually benign, although minor necrotic lesions have occasionally been reported. Bites by the Northwestern brown spider or hobo spider (Tegenaria agrestis) have been associated with minor necrotic lesions somewhat more frequently. Bites by L. reclusa are sometimes associated with large area of necrosis and systemic toxicity (loxoscelism). The initial reaction often consists of erythema and pain or pruritus. A small vesicle may form at the bite area, and the lesion may take on a "bull's eye" or "halo" appearance, having a central vesicle surrounded by an erythematous and ecchymotic area. A blanched ring may surround the discolored area. The vesicle may rupture, exposing an ulcer.
    2) SEVERE TOXICITY: In severe cases cutaneous necrosis may occur and may extend to involve subcutaneous fat and muscle. The extent of local tissue injury is dependent on the amount of venom diffused following a L. reclusa envenomations. Systemic effects may develop, usually 24 to 72 hours after envenomation. Mild systemic effects include fever, chills, myalgias, arthralgias and generalized rash. Rarely, severe systemic effects may include hemolysis, jaundice, renal failure and shock. Systemic reactions are related to the degree of envenomation and not necessarily to the severity of skin lesions.
    0.2.3) VITAL SIGNS
    A) Fever and tachycardia are common in patients with systemic effects.
    0.2.14) DERMATOLOGIC
    A) In most cases local pain or a burning sensation develops within the first 10 minutes. A small vesicle may form at the bite area. The lesion may take on a "bull's eye" or "halo" appearance, having a central vesicle surrounded by an erythematous and ecchymotic area. A blanched ring may surround the discolored area. The vesicle may rupture, exposing an ulcer. Occasionally, the ulcer may enlarge and involve underlying tissues, including muscle.
    B) A generalized pruritic morbilliform rash may develop over the trunk and extremities, usually during the first 24 to 72 hours.
    0.2.20) REPRODUCTIVE
    A) Two cases of L. reclusa envenomation during the third trimester of pregnancy have been documented. Maternal symptoms were mild and both delivered healthy infants.

Laboratory Monitoring

    A) Monitor CBC for evidence of hemolysis in patients with systemic symptoms. In severe envenomations follow platelet count, INR or PT, PTT, urinalysis, urine output, and renal function tests.
    B) Type and crossmatch carefully in patients with evidence of hemolysis, as venom may alter results of ABO compatibility tests.
    C) The peripheral smears may show increased numbers of spherocytes, polychromasia, nucleated red blood cells, Heinz bodies, immature myeloid cells, and evidence of erythrophagocytosis.
    D) Monitor CPK in patients with systemic symptoms. Rhabdomyolysis has been reported following severe envenomation. Monitor LDH and serum potassium in patients with hemolysis.

Treatment Overview

    0.4.7) BITES/STINGS
    A) MANAGEMENT OF MILD TO MODERATE TOXICITY
    1) WOUND CARE: Most bites require little more than local care. Diphenhydramine 5 mg/kg/day orally, with a maximum of 25 to 50 mg every 6 hours may be effective in relieving pruritus. Antibiotics are only indicated for a confirmed infection. For mild pain relief nonnarcotic analgesics are indicated. For moderate to severe pain, narcotic analgesics may be given. Ice may be applied locally. Tetanus status should be determined and updated for any penetrating wound. A variety of drugs and procedures have been advocated to reduce the extent of tissue necrosis, but none have been proven effective in controlled trials. The majority of patients do well with good local wound care alone, and serious complications or the need for skin grafting are not common.
    2) INEFFECTIVE/POTENTIALLY HARMFUL TREATMENT: Dapsone, corticosteroids, wound excision, and hyperbaric oxygen have all been advocated to reduce tissue necrosis. None of these therapies have been proven effective and they are not routinely recommended. Dapsone, has produced methemoglobinemia as an adverse effect of treatment and early wound excision has been associated with worse scarring.
    3) SYSTEMIC EFFECTS: Symptomatic and supportive care may be all that is required for systemic effects of nausea and vomiting and mild hemolysis. Patients should be followed closely if systemic effects occur.
    B) MANAGEMENT OF SEVERE TOXICITY
    1) WOUND CARE: Large, slow healing ulcers may become infected and require antibiotic therapy and skin grafts.
    2) SYSTEMIC EFFECTS: Transfusion may be necessary in patients with severe hemolysis. Ensure adequate urine output in patients with hemolysis.
    C) ONSET OF SYMPTOMS
    1) An erythematous wheal appears within 30 minutes. Systemic effects, if they develop, usually do so 24 to 48 hours after envenomation.
    D) DURATION OF EFFECTS
    1) Nausea and abdominal cramps, as well as anxiety, headache, and a subnormal temperature usually subside within 24 hours. The macule at the bite site may persist for several days. The bite site gradually heals, usually within a month.
    E) ANTIDOTE
    1) There is no antivenom or other specific antidote in the US. In South America, there are 2 antivenoms available from the Brazilian Ministry of Health: antiloxoscelic serum and anti-arachnidic serum.
    F) CONTRAINDICATED
    1) Electric shock therapy for the treatment of envenomation is contraindicated.
    G) PATIENT DISPOSITION
    1) HOME CRITERIA: Patients without evidence of hemolysis, severe systemic effects, or major wound complications can be followed as outpatients with careful serial evaluations for evidence of hemolysis and wound progression.
    2) OBSERVATION CRITERIA: Patients with systemic symptoms, an enlarging wound or symptoms of infection should be referred to a healthcare provider.
    3) ADMISSION CRITERIA: Patients with evidence of hemolysis, significant infection, severe systemic effects, or complicated wounds require hospital admission.
    4) CONSULT CRITERIA: A toxicologist or regional poison center should be consulted about the care of patients with severe local or systemic effects and should be notified of bites presenting to healthcare providers for purposes of data collection.
    H) PITFALLS
    1) Falsely attributing a dermonecrotic wound to a spider bite may prevent the timely diagnosis of another medical condition.
    I) DIFFERENTIAL DIAGNOSIS
    1) Includes erythema chronicum migrans, Stevens-Johnson syndrome, toxic epidermal necrolysis, lymphomatoid papulosis, erythema nodosum, erythema multiforme, chronic and infected herpes simplex, herpes zoster, gonococcal arthritis-dermatitis, purpura fulminans, diabetic ulcer, bedsores, poison oak, poison ivy, periarteritis nodosum, pyoderma gangrenosum, keratin-mediated response to a fungus, scleroderma, malignancy causing arterial obstruction, hypersensitivity angiitis and Lyme disease.

Range Of Toxicity

    A) TOXICITY: A toxic dose has not been established. While a single bite can cause systemic loxoscelism, it is estimated that less than 15% of brown recluse bites result in significant effects (eg, significant scarring, chronic skin lesions, hospitalization) and systemic loxoscelism is relatively rare.

Summary Of Exposure

    A) ORGANISM: Loxosceles spiders are distributed in discreet populations across the US, primarily in the Midwest and Southwest. Loxosceles species include: L. reclusa, L. refescens, L. lacta, L. unicolor, L. deserta, L. arizonica, and others. These spiders are often found in ground cover or in plants as well as in human dwellings. They may have a distinct violin-shaped mark on the dorsum of the cephalothorax and can be differentiated from other spiders by their set of 6 eyes (in 3 pairs) rather than the 8 eyes seen in most other spider species. It is likely that some, if not many dermonecrotic lesions attributed to spider bites are from other causes.
    B) TOXICOLOGY: The venom of Loxosceles species is composed of a number of proteins, enzymes, and nonenzymatic polypeptides. Brown recluse venom contains sphingomyelinase among other toxins and component synergism may play a part in the overall tissue response. Perhaps more important is the response of host cells to the presence of a complement-mediating foreign substance. Loxosceles venom has been shown to be a potent inducer of multiple inflammatory mediating chemokines. Venom toxins may act as proteases upon molecular constituents of plasma extracellular matrix and basement membrane constituents producing hemorrhage, delayed wound healing and renal failure, as well as the spreading of other noxious toxins.
    C) EPIDEMIOLOGY: Painful bites may be noticed immediately and the offending spider seen, but many are not appreciated at the time and a diagnosis is made in retrospect from a characteristic history and physical examination. The incidence of necrotic arachnidism is unknown; there are no definitive diagnostic tests, and it is likely that some dermonecrotic lesions are falsely attributed to spider bites. In 2008, there were over 4,000 cases of spider or unknown insect bite reported to US poison centers, of which over 1700 were coded as "Brown Recluse" or "Necrotizing, other". Eleven major outcomes were reported, but no deaths.
    D) WITH POISONING/EXPOSURE
    1) MILD TO MODERATE TOXICITY: Bites by most of the species of spiders listed above are usually benign, although minor necrotic lesions have occasionally been reported. Bites by the Northwestern brown spider or hobo spider (Tegenaria agrestis) have been associated with minor necrotic lesions somewhat more frequently. Bites by L. reclusa are sometimes associated with large area of necrosis and systemic toxicity (loxoscelism). The initial reaction often consists of erythema and pain or pruritus. A small vesicle may form at the bite area, and the lesion may take on a "bull's eye" or "halo" appearance, having a central vesicle surrounded by an erythematous and ecchymotic area. A blanched ring may surround the discolored area. The vesicle may rupture, exposing an ulcer.
    2) SEVERE TOXICITY: In severe cases cutaneous necrosis may occur and may extend to involve subcutaneous fat and muscle. The extent of local tissue injury is dependent on the amount of venom diffused following a L. reclusa envenomations. Systemic effects may develop, usually 24 to 72 hours after envenomation. Mild systemic effects include fever, chills, myalgias, arthralgias and generalized rash. Rarely, severe systemic effects may include hemolysis, jaundice, renal failure and shock. Systemic reactions are related to the degree of envenomation and not necessarily to the severity of skin lesions.

Vital Signs

    3.3.1) SUMMARY
    A) Fever and tachycardia are common in patients with systemic effects.
    3.3.3) TEMPERATURE
    A) Fever is common in patients with systemic effects and may develop more often in children (Way et al, 2005; Donepudi et al, 2005; Wright et al, 1997) (Schenone & Parts, 1961)(Rauber, 1983; Madrigal et al, 1972; Chu et al, 1978; Eichner, 1984; Baldwin et al, 1988; Cacy & Mold, 1999). Fever with chills and night sweats has also been reported (Sams et al, 2001).
    B) It may develop within 8 hours of the bite (Rees et al, 1985) and may persist for days in the absence of documented infection (Bernstein & Ehrlich, 1986).
    3.3.5) PULSE
    A) Tachycardia may develop in patients with fever or hemolysis (Madrigal et al, 1972; Minton & Olson, 1964; Majeski & Durst, 1976).

Heent

    3.4.6) THROAT
    A) CASE REPORTS: Pharyngeal irritation was reported in several individuals after consuming deep-fried Chilean rose-haired tarantula (Grammostola spatulata) as part of a group undertaking novel experiences. Although the spiders were "blow torched", the remaining spiders were examined by an entomologist that confirmed the presence of urticating hairs on the spider's abdomen (Traub et al, 2001).
    B) LOXOSCELISM: An 11-year-old boy presented with fever (up to 104 degrees F), pharyngitis, erythematous rash (over his ears, scalp, neck, trunk, buttocks, and proximal extremities), and a necrotic lesion on the lobule of the left ear after a brown recluse spider bite (Donepudi et al, 2005).

Cardiovascular

    3.5.2) CLINICAL EFFECTS
    A) TACHYARRHYTHMIA
    1) WITH POISONING/EXPOSURE
    a) Tachycardia may develop in patients with fever or significant hemolysis (Madrigal et al, 1972; Minton & Olson, 1964; Majeski & Durst, 1976).
    B) HYPOTENSIVE EPISODE
    1) WITH POISONING/EXPOSURE
    a) Cardiovascular collapse has been described in several cases of presumed L. reclusa envenomation with severe hemolysis (Lessenden & Zimmer, 1960; Nicholson & Nicholson, 1962; Riley et al, 1964; Taylor & Denny, 1966; Vorse et al, 1972).
    b) CASE REPORT: A 6-year-old boy developed massive hemolysis, disseminated intravascular coagulopathy, shock (BP 77/47 mm Hg) and acute renal failure after a suspected loxoscelism envenomation. The patient was initially admitted with a one day history of abdominal pain, nausea, vomiting and intermittent fever following a presumed spider bite; a dead spider was found by the mother in the child's bed (Note: there is no report that the spider was identified at home or brought to the hospital for identification). He had erythroderma and 2 large, bullous lesions with ecchymotic and erythematous bases on his lower abdomen. His initial laboratory studies were significant for an elevated WBC and coagulation abnormalities (ie, prothrombin time 30.1; partial thromboplastin time 65.6; and INR 2.96) and dark urine that was positive for hemoglobin and myoglobin. The patient required immediate intubation with fluid resuscitation and red blood cell transfusion. The patient required dopamine and epinephrine for ongoing hypotension. Further laboratory analysis was not possible due to massive hemolysis. Due to the presence of anuria, metabolic acidosis, hyperkalemia, and ongoing need for blood products, the patient was started on plasma exchange therapy (PEX) for hemolyzed plasma and continuous venovenous hemodiafiltration (CVVH). Over the next few weeks, the child gradually improved. By day 8, he was weaned off all inotropes and his neurologic function was normal. Hemolysis slowly resolved and PEX was discontinued on day 9 and CVVH was gradually weaned as his urine output increased. CVVH was discontinued on day 11 and the following day he was successfully extubated. He was discharged to home on day 28 with maintenance amlodipine therapy and no permanent sequelae (Said et al, 2014).

Respiratory

    3.6.2) CLINICAL EFFECTS
    A) DYSPNEA
    1) WITH POISONING/EXPOSURE
    a) Respiratory difficulty developed in three of 22 subjects who sustained bites presumed to be from Tegenaria arestis (Vest, 1987).
    B) EDEMA
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 7-year-old boy developed rapidly progressing neck swelling secondary to a brown recluse spider bite. Initially, the patient did not have any respiratory distress, but the edema progressed to include the clavicles and the upper chest. He complained of shortness of breath approximately 40 hours after exposure. Oxygen saturation on room air and a chest x-ray were both normal. Fiberoptic laryngoscopy showed mild edema of the glottis and supraglottis with normal vocal cord function and an adequate airway. Treatment included intravenous steroids, subcutaneous susphrine, and oral diphenhydramine. On hospital day 2, swelling had decreased and the patient did not complain of any further respiratory difficulty. He was discharged to home on day 5 (Goto et al, 1996).

Neurologic

    3.7.2) CLINICAL EFFECTS
    A) HEADACHE
    1) WITH POISONING/EXPOSURE
    a) Persistent headache is common in patients with systemic effects (Eichner, 1984; Minton & Olson, 1964; Vorse et al, 1972; Vest, 1987; Sams et al, 2001).
    B) ALTERED MENTAL STATUS
    1) WITH POISONING/EXPOSURE
    a) Mental status changes ranging from confusion to lethargy to coma have been reported in severe suspected Loxosceles envenomations (Vorse et al, 1972; Schenone & Prats, 1961; Majeski & Durst, 1976).
    b) Visual disturbances, hallucinations, disorientation and confusion have been reported after bites presumed to be from Tegenaria agrestis (Vest, 1987).
    C) PARESTHESIA
    1) WITH POISONING/EXPOSURE
    a) Persistent anesthesia and dysesthesia over the area of the bite has been reported (Longfield, 1981; Gross et al, 1990).
    D) MYELITIS
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 19-year-old man developed transverse myelitis with partial permanent paralysis from occlusion of the anterior vertebral artery after a presumed L. reclusa bite (Wasserman & Anderson, 1984).
    E) INTRACRANIAL HEMORRHAGE
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: Subdural hematoma was discovered on autopsy of a 6 year old boy who developed severe hemolysis and DIC after a presumed L. reclusa bite (Vorse et al, 1972).
    F) SEIZURE
    1) WITH POISONING/EXPOSURE
    a) Seizures have been reported with severe presumed L. reclusa envenomations, but are rare (Majeski & Durst, 1976; Edwards et al, 1980).

Gastrointestinal

    3.8.2) CLINICAL EFFECTS
    A) VOMITING
    1) WITH POISONING/EXPOSURE
    a) Nausea and vomiting may develop in patients with systemic effects (Russell et al, 1969; Madrigal et al, 1972; Eichner, 1984; Rees et al, 1985; Bradley & Starkey, 1988; Sams et al, 2001).
    B) DIARRHEA
    1) WITH POISONING/EXPOSURE
    a) Diarrhea was reported in a 72-year-old man one week after receiving a suspected envenomation by a brown recluse spider (Andersen et al, 2010).
    C) LOSS OF APPETITE
    1) WITH POISONING/EXPOSURE
    a) Anorexia was described in five of 22 subjects who sustained bites presumed to be from Tegenaris arestis (Vest, 1987).

Genitourinary

    3.10.2) CLINICAL EFFECTS
    A) HEMOGLOBINURIA
    1) WITH POISONING/EXPOSURE
    a) Hemoglobinuria is reported in patients with hemolysis (Donepudi et al, 2005; Rauber, 1983; Chu et al, 1978; Madrigal et al, 1972) (Anderson, 1991)(Vorse et al, 1972) (Schenone & Parts, 1961) (Eichner, 1984).
    b) Proteinuria and mild glycosuria have also been reported (Donepudi et al, 2005; Madrigal et al, 1972; Minton & Olson, 1964) (Anderson, 1991).
    B) ACUTE RENAL FAILURE SYNDROME
    1) WITH POISONING/EXPOSURE
    a) Acute tubular necrosis with resulting oliguria or anuria may develop in patients with severe hemolysis (Vorse et al, 1972; Schenone & Prats, 1961; Yarbrough, 1987).
    b) CASE REPORT: A 71-year-old man presented to the hospital 5 days after a spider bite with a severe kidney failure, hemolysis, metabolic acidosis, and clotting disorder. He was diagnosed with viscerocutaneous loxoscelism. He died 5 weeks after admission despite supportive care (Zambrano et al, 2005).
    c) CASE REPORT: A 6-year-old boy developed massive hemolysis, disseminated intravascular coagulopathy, shock (BP 77/47 mm Hg) and acute renal failure after a suspected loxoscelism envenomation. The patient was initially admitted with a one day history of abdominal pain, nausea, vomiting and intermittent fever following a presumed spider bite; a dead spider was found by the mother in the child's bed (Note: there is no report that the spider was identified at home or brought to the hospital for identification). He had erythroderma and 2 large, bullous lesions with ecchymotic and erythematous bases on his lower abdomen. His initial laboratory studies were significant for an elevated WBC and coagulation abnormalities (ie, prothrombin time 30.1; partial thromboplastin time 65.6; and INR 2.96) and dark urine that was positive for hemoglobin and myoglobin. The patient required immediate intubation with fluid resuscitation and red blood cell transfusion. The patient required dopamine and epinephrine for ongoing hypotension. Further laboratory analysis was not possible due to massive hemolysis. Due to the presence of anuria, metabolic acidosis, hyperkalemia, and ongoing need for blood products, the patient was started on plasma exchange therapy (PEX) for hemolyzed plasma and continuous venovenous hemodiafiltration (CVVH). Over the next few weeks, the child gradually improved. By day 8, he was weaned off all inotropes and his neurologic function was normal. Hemolysis slowly resolved and PEX was discontinued on day 9 and CVVH was gradually weaned as his urine output increased. CVVH was discontinued on day 11 and the following day he was successfully extubated. He was discharged to home on day 28 with maintenance amlodipine therapy and no permanent sequelae (Said et al, 2014).

Acid-Base

    3.11.2) CLINICAL EFFECTS
    A) ACIDOSIS
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: Metabolic acidosis has been reported in a 6-year-old boy with severe hemolysis and DIC secondary to presumed L. reclusa envenomation (Vorse et al, 1972).
    b) CASE REPORT: A 71-year-old man presented to the hospital 5 days after a spider bite with a severe kidney failure, hemolysis, metabolic acidosis, and clotting disorder. He was diagnosed with viscerocutaneous loxoscelism. He died 5 weeks after admission despite supportive care (Zambrano et al, 2005).

Hematologic

    3.13.2) CLINICAL EFFECTS
    A) HEMOLYSIS
    1) WITH POISONING/EXPOSURE
    a) Acute intravascular hemolysis is not uncommon in severe envenomations (Rauber, 1983; Chu et al, 1978; Madrigal et al, 1972; Eichner, 1984; Yarbrough, 1987; Wasserman, 1988). In a retrospective review of 111 patients with suspected brown recluse spider bites treated during a 30-month period, mild hemolysis was reported in only one patient (Wright et al, 1997).
    b) LABORATORY FINDINGS: Low hematocrit, hemoglobinuria, elevated plasma hemoglobin and direct bilirubin, and elevations of serum potassium, LDH and SGOT may develop with hemolysis.
    c) PERIPHERAL SMEAR: The peripheral smear may show increased numbers of spherocytes, polychromasia, nucleated red blood cells, Heinz bodies, immature myeloid cells, and evidence of erythrophagocytosis (Way et al, 2005; Eichner, 1984; Chu et al, 1978).
    d) COOMBS' TEST: May be positive (Eichner, 1984).
    e) PEDIATRIC: Red blood cells from a child with hemolysis from presumed L. reclusa envenomation were found to be reactive by indirect antiglobulin test with most ABO-compatible serum samples (Hardman et al, 1983).
    B) LEUKOCYTOSIS
    1) WITH POISONING/EXPOSURE
    a) Leukocytosis and a left shift are common findings (Way et al, 2005; Eichner, 1984; Bernstein & Ehrlich, 1986).
    b) CASE REPORT: An 11-year-old boy presented with fever (up to 104 degrees F), pharyngitis, erythematous rash (over his ears, scalp, neck, trunk, buttocks, and proximal extremities), and a necrotic lesion on the lobule of the left ear after a brown recluse spider bite. The lesion on the lobule developed a significant eschar on its anterior and posterior surface over 4 days. The eschar auto-amputated with a significant soft tissue defect. He also developed leukocytosis (WBC 22,400 cells/mm(3); previously 14,500 cells/mm(3)), hemolytic anemia, and proteinuria. He was diagnosed with systemic loxoscelism. Following 4 days of supportive care, he recovered and was discharged (Donepudi et al, 2005).
    C) THROMBOCYTOPENIC DISORDER
    1) WITH POISONING/EXPOSURE
    a) Thrombocytopenia may occur (Chu et al, 1978; Vorse et al, 1972).
    D) HEMOLYTIC ANEMIA
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 9-year-old boy presented with fever (102 degrees F), myalgias and a pruritic rash with a draining flank wound following a brown recluse bite one day prior to admission. Laboratory evidence of hemolytic anemia was present and included: hemoglobin 10.4 g/dL, hematocrit 25.8%, mean corpuscular volume 89.0 cm mcgm, total bilirubin 1.3 mg/dL with an indirect component of 1.1 mg/dL, and normal liver transaminases. Urinalysis was normal. A peripheral smear collected after admission was positive for shistocytes and Heinz bodies further supporting the diagnosis of intravascular hemolysis. The patient required 2 units of packed red blood cells by day 3 for a persistent decline in hematocrit (lowest 13.4%), which stabilized by day 6 (Way et al, 2005).
    b) CASE REPORT: An 11-year-old boy presented with fever (up to 104 degrees F), pharyngitis, erythematous rash (over his ears, scalp, neck, trunk, buttocks, and proximal extremities), and a necrotic lesion on the lobule of the left ear after a brown recluse spider bite. The lesion on the lobule developed a significant eschar on its anterior and posterior surface over 4 days. The eschar auto-amputated with a significant soft tissue defect. He also developed leukocytosis, hemolytic anemia (hematocrit 26.5%; previously 31.6%), and proteinuria. He was diagnosed with systemic loxoscelism. Following 4 days of supportive care, he recovered and was discharged (Donepudi et al, 2005).
    E) DISSEMINATED INTRAVASCULAR COAGULATION
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: Hemolysis, thrombocytopenia, prolonged PT and PTT, decreased fibrinogen and increased fibrin split products developed in a 6-year-old boy with severe envenomation presumed to be secondary to L. reclusa bite (Vorse et al, 1972).
    b) CASE REPORT: A 71-year-old man presented to the hospital 5 days after a spider bite with a severe kidney failure, hemolysis, metabolic acidosis, and clotting disorder. He was diagnosed with viscerocutaneous loxoscelism. He died 5 weeks after admission despite supportive care (Zambrano et al, 2005).
    c) CASE REPORT: A 6-year-old boy developed massive hemolysis, disseminated intravascular coagulopathy, shock (BP 77/47 mm Hg) and acute renal failure after a suspected loxoscelism envenomation. The patient was initially admitted with a one day history of abdominal pain, nausea, vomiting and intermittent fever following a presumed spider bite; a dead spider was found by the mother in the child's bed (Note: there is no report that the spider was identified at home or brought to the hospital for identification). He had erythroderma and 2 large, bullous lesions with ecchymotic and erythematous bases on his lower abdomen. His initial laboratory studies were significant for an elevated WBC and coagulation abnormalities (ie, prothrombin time 30.1; partial thromboplastin time 65.6; and INR 2.96) and dark urine that was positive for hemoglobin and myoglobin. The patient required immediate intubation with fluid resuscitation and red blood cell transfusion. The patient required dopamine and epinephrine for ongoing hypotension. Further laboratory analysis was not possible due to massive hemolysis. Due to the presence of anuria, metabolic acidosis, hyperkalemia, and ongoing need for blood products, the patient was started on plasma exchange therapy (PEX) for hemolyzed plasma and continuous venovenous hemodiafiltration (CVVH). Over the next few weeks, the child gradually improved. By day 8, he was weaned off all inotropes and his neurologic function was normal. Hemolysis slowly resolved and PEX was discontinued on day 9 and CVVH was gradually weaned as his urine output increased. CVVH was discontinued on day 11 and the following day he was successfully extubated. He was discharged to home on day 28 with maintenance amlodipine therapy and no permanent sequelae (Said et al, 2014).
    3.13.3) ANIMAL EFFECTS
    A) ANIMAL STUDIES
    1) THROMBOCYTOPENIA
    a) DOGS: Marked thrombocytopenia and moderate hemolysis developed in each of 15 dogs injected with either crude extract of macerated L. reclusa, venom from milked spiders, or lyophilized pooled venom. Direct hemolytic activity of lyophilized venom was noted on human red blood cells in vitro (Denny et al, 1964).
    b) RABBITS: Thrombocytopenia, decreased fibrinogen, and prolonged Lee White clotting time with normal PT and PTT developed in rabbits injected with L. reclusa venom (Berger, 1973).

Dermatologic

    3.14.1) SUMMARY
    A) In most cases local pain or a burning sensation develops within the first 10 minutes. A small vesicle may form at the bite area. The lesion may take on a "bull's eye" or "halo" appearance, having a central vesicle surrounded by an erythematous and ecchymotic area. A blanched ring may surround the discolored area. The vesicle may rupture, exposing an ulcer. Occasionally, the ulcer may enlarge and involve underlying tissues, including muscle.
    B) A generalized pruritic morbilliform rash may develop over the trunk and extremities, usually during the first 24 to 72 hours.
    3.14.2) CLINICAL EFFECTS
    A) PAIN
    1) WITH POISONING/EXPOSURE
    a) Pain or stinging may occur with the initial bite (Madrigal et al, 1972; Bradley & Starkey, 1988). Worsening pain, a burning sensation and pruritus may develop as the lesion progresses (Wand, 1972; Baldwin et al, 1988; Russell et al, 1969) Anderson, 1991; (Berger, 1973).
    b) CASE SERIES: In a retrospective review of 19 documented cases of L. reclusa envenomation, the most common presenting symptom was pain at the site (most bites occurred on the extremities). In one patient, persistent pain required two lumbar sympathetic blocks (Sams et al, 2001).
    B) BITE - WOUND
    1) WITH POISONING/EXPOSURE
    a) Initial erythema surrounding the bite site is very common. The extremities are common areas for exposure (67% of exposures), but may also occur on the trunk or head and neck region (Cacy & Mold, 1999). This may progress to a "target lesion" with an erythematous central vesicle or puncta surrounded by a blanched ring which may in turn be surrounded by an erythematous ring (Berger, 1973; Russell et al, 1969; Anderson, 1987). A characteristic presentation of the site following a bite has been described as the "red, white, and blue" sign (erythema, ischemia, and necrosis) (Masters, 1998).
    b) CASE REPORT: A 13-year-old girl developed dermonecrotic ulcer on her eyelid after a bite by a presumed L. spider. She developed no evidence of systemic reaction. She was treated with supportive care and erythema and edema resolved in one week (Bilgili et al, 2013).
    c) CASE SERIES: In a retrospective review of 19 documented cases of L. reclusa envenomation, all patients presented with localized erythema (Sams et al, 2001).
    C) SKIN NECROSIS
    1) WITH POISONING/EXPOSURE
    a) The central vesicle may become sunken and dark purple or black and rupture, exposing an ulcer (Bradley & Starkey, 1988; Anderson, 1982a).
    b) In severe cases, necrosis may involve large areas and extend into fat and muscle (Lewis & Regan, 1966; Russell et al, 1969; Edwards et al, 1980; Alario et al, 1987; Baldwin et al, 1988; Hoover et al, 1990).
    c) In lesions destined to develop significant necrosis, bullae and hemorrhage have usually developed by 24 hours (Berger, 1973a).
    d) CASE REPORT: A 22-year-old woman was bitten on the ear by a presumed Mediterranean recluse and she developed immediate pain which was followed by swelling of the face and a rash covering her entire body 48 hours after envenomation. Initial treatment included antihistamines but did not improve ear pain and by day 12 necrosis of the middle third of the ear was observed. Approximately 5 months later, partial reconstruction of the ear was required which was followed by a full thickness skin graft to close the posterior side of the ear (Holtslag et al, 2014).
    e) CASE SERIES: In a retrospective review of 19 documented cases of L. reclusa envenomation, 11 patients (58%) had skin necrosis; 32% of those individuals had areas of necrosis larger than 1 cm(2). Time to healing was variable, and ranged from 5 days to more than 17 weeks (mean, 5.6 weeks). With severe lesions (grade 3; a total of 6 patients) average time to healing was 74 days; 22 days for moderate lesions (grade 2; a total of 5 patients), and 8 days for mild lesions (grade 1; a total of 8 patients). Tissue response was variable and ranged from mild erythema to severe cutaneous necrosis. Violaceous discoloration at presentation was indicative of incipient necrosis, and was present in 8 patients. Scarring was reported in 3 patients; chronic ulceration did not occur (Sams et al, 2001).
    f) CASE SERIES/INCIDENCE: In a retrospective review of 149 possible brown recluse spider bites, skin necrosis was present in 41% of bites (Cacy & Mold, 1999).
    g) SKIN GRAFTING: In a retrospective review of 111 patients with suspected brown recluse spider bites treated during a 30-month period, most bites required only supportive care and delayed skin grafting was only required in 3 cases (two of the three patients had been prescribed dapsone during the early phase of illness) (Wright et al, 1997).
    h) LAMPONA SPECIES: Blistering, ulceration, pain and skin necrosis were found in 14 cases of spider bites thought to be from the white-tailed spider (note: only 3 cases were confirmed). One patient required amputation of the hand and distal forearm. In nine of the patients, the necrosis reoccurred (Pincus et al, 1999). Another patient had 2 reoccurrences of necrotic arachnidism in the 12 months following a bite by a white-tailed spider (Chan, 1998).
    D) ACRAL ERYTHEMA
    1) WITH POISONING/EXPOSURE
    a) HAND-FOOT SYNDROME
    1) Hand-foot syndrome, a rare disorder characterized by painful erythema on the palms and soles of the feet, was described in a healthy adult 3 days after being bitten by a brown spider. Biopsies of the hand lesions showed subacute angiocentric dermatitis. Serology studies were negative. Treatment included topical steroids, cold compresses, and antihistamines (Farah et al, 2006).
    E) GANGRENE
    1) WITH POISONING/EXPOSURE
    a) Recurrent, chronic, indolent areas of ulceration, inflammation and infections similar to pyoderma gangrenosum have been reported in 5 patients with presumed L. reclusa envenomation (Hoover et al, 1990; Rees et al, 1985).
    F) MACULOPAPULAR ERUPTION
    1) WITH POISONING/EXPOSURE
    a) A generalized morbilliform rash may develop in patients with systemic effects (Russell et al, 1969; Bradley & Starkey, 1988) (Anderson, 1991) (Berger, 1973; Ingber et al, 1991).
    b) INCIDENCE: In a retrospective review of 111 patients with suspected brown recluse spider bites treated during a 30-month period, 24 patients (22%) developed a secondary rash, usually described as maculopapular or consisting of "island lesions" (Wright et al, 1997).

Musculoskeletal

    3.15.2) CLINICAL EFFECTS
    A) MUSCLE PAIN
    1) WITH POISONING/EXPOSURE
    a) Myalgias, arthralgias and general weakness are common symptoms in patients with systemic effects (Russell et al, 1969; Wasserman & Anderson, 1984; Sams et al, 2001).
    B) RHABDOMYOLYSIS
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 20-year-old man was bitten on the neck by a Loxosceles arizonica (entomologist-identified) and initially developed pain, muscle cramping, tremulousness, and fever (103.4 degrees F). Two days later, the patient had a macular rash and a CPK of 17,000 U/L; total bilirubin of 3.5 mg/dL; platelets 120,000/mm(3); creatinine 1.4 mg/dL; SGOT 175 U/L; and an elevated urine myoglobin. Treatment included intravenous hydration, antibiotics, and urinary alkalinization. CPK peaked at 24,503 U/L and SGOT at 182 U/L. Labs were improving by day five. At 2 weeks the patient was clinically improved with a resolving dermatonecrosis (Seifert et al, 2000).

Reproductive

    3.20.1) SUMMARY
    A) Two cases of L. reclusa envenomation during the third trimester of pregnancy have been documented. Maternal symptoms were mild and both delivered healthy infants.
    3.20.3) EFFECTS IN PREGNANCY
    A) CASE SERIES
    1) Two cases of documented L. reclusa envenomation and three of suspected L. reclusa envenomations have been described in women during the third trimester of pregnancy. All envenomation syndromes were mild and resolved rapidly, and all five women subsequently delivered healthy infants (Anderson, 1982).

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) Monitor CBC for evidence of hemolysis in patients with systemic symptoms. In severe envenomations follow platelet count, INR or PT, PTT, urinalysis, urine output, and renal function tests.
    B) Type and crossmatch carefully in patients with evidence of hemolysis, as venom may alter results of ABO compatibility tests.
    C) The peripheral smears may show increased numbers of spherocytes, polychromasia, nucleated red blood cells, Heinz bodies, immature myeloid cells, and evidence of erythrophagocytosis.
    D) Monitor CPK in patients with systemic symptoms. Rhabdomyolysis has been reported following severe envenomation. Monitor LDH and serum potassium in patients with hemolysis.
    4.1.2) SERUM/BLOOD
    A) HEMATOLOGY
    1) Monitor for evidence of hemolysis. In severe envenomations follow platelet count, INR or PT, PTT, and renal function tests. Type and crossmatch in patients with evidence of hemolysis, as venom may alter results of ABO compatibility tests.
    a) Hemolytic anemia usually presents with a low hematocrit and a normal mean corpuscular volume, along with an elevated total and indirect bilirubin with normal liver transaminases. Indirect hyperbilirubinemia develops as a result of hemolysis as hemoglobin is converted to bilirubin and the conjugation process is overwhelmed leading to unconjugated bilirubin in the blood (Way et al, 2005).
    b) PERIPHERAL SMEAR: The peripheral smear may show increased numbers of spherocytes, polychromasia, nucleated red blood cells, Heinz bodies, immature myeloid cells, and evidence of erythrophagocytosis (Way et al, 2005; Eichner, 1984; Chu et al, 1978).
    B) BIOCHEMISTRY
    1) Monitor CPK as indicated. Rhabdomyolysis has been reported following severe envenomation. Monitor LDH and serum potassium in patients with hemolysis.
    4.1.4) OTHER
    A) OTHER
    1) OTHER
    a) If dapsone therapy is considered, testing patients for G6PD deficiency is recommended prior to initiating therapy.

Methods

    A) IMMUNOASSAY
    1) An enzyme-linked immunosorbent assay (ELISA) designed to detect Loxosceles venom was able to detect the venom from a non-necrotic lesion 3 days after exposure by moistening a cotton swab with normal saline and gently rubbing the inflamed skin for 30 seconds. A serum sample had an absorbance at the background level with this assay. The authors suggested that this assay could provide a noninvasive method to collect a sample and confirm the presence of Loxosceles envenomation in endemic areas or following an atypical or small bite (Stoecker et al, 2006). This assay is not available for clinical use.
    2) A venom-specific enzyme immunoassay (EIA) was able to detect the presence of Loxosceles venom from a lesional punch skin biopsy tissue and in hairs plucked from a suspicious skin lesion of an adult. The authors suggested that by using this Loxosceles-specific immunoassay, venom could be detected in dermonecrotic skin and hair specimens for up to 4 days after envenomation (Miller et al, 2000).
    3) An in vitro lymphocyte transformation test that detects serologic evidence of immunity to L. reclusa venom has been developed, but is not in use clinically (Berger, 1973).
    4) An ELISA assay for detection of IgG antibodies to L. gaucho venom has been described, but is not used clinically (Barbaro et al, 1992).
    5) An ELISA assay for detection of L. gaucho venom in wound tissue has been described (Cardoso et al, 1990).
    B) OTHER
    1) A specific, passive hemagglutination inhibition test has been described for diagnosis of L. reclusa envenomation in biologic samples (Barrett et al, 1993). Additional studies are needed to determine the clinical value of this technique.

Life Support

    A) Support respiratory and cardiovascular function.

Patient Disposition

    6.3.6) DISPOSITION/BITE-STING EXPOSURE
    6.3.6.1) ADMISSION CRITERIA/BITE-STING
    A) Patients with evidence of hemolysis, significant infection, severe systemic effects, or complicated wounds require hospital admission.
    6.3.6.2) HOME CRITERIA/BITE-STING
    A) Patients without evidence of hemolysis, severe systemic effects, or major wound complications can be followed as outpatients with careful serial evaluations for evidence of hemolysis and wound progression.
    6.3.6.3) CONSULT CRITERIA/BITE-STING
    A) A toxicologist or regional poison center should be consulted about the care of patients with severe local or systemic effects and should be notified of bites presenting to healthcare providers for purposes of data collection.
    6.3.6.5) OBSERVATION CRITERIA/BITE-STING
    A) Patients with systemic symptoms, an enlarging wound or symptoms of infection should be referred to a healthcare provider.

Monitoring

    A) Monitor CBC for evidence of hemolysis in patients with systemic symptoms. In severe envenomations follow platelet count, INR or PT, PTT, urinalysis, urine output, and renal function tests.
    B) Type and crossmatch carefully in patients with evidence of hemolysis, as venom may alter results of ABO compatibility tests.
    C) The peripheral smears may show increased numbers of spherocytes, polychromasia, nucleated red blood cells, Heinz bodies, immature myeloid cells, and evidence of erythrophagocytosis.
    D) Monitor CPK in patients with systemic symptoms. Rhabdomyolysis has been reported following severe envenomation. Monitor LDH and serum potassium in patients with hemolysis.

Oral Exposure

    6.5.3) TREATMENT
    A) SUPPORT
    1) See bite/stings section for further information.

Enhanced Elimination

    A) HEMODIALYSIS
    1) Hemodialysis is indicated for renal failure.

Summary

    A) TOXICITY: A toxic dose has not been established. While a single bite can cause systemic loxoscelism, it is estimated that less than 15% of brown recluse bites result in significant effects (eg, significant scarring, chronic skin lesions, hospitalization) and systemic loxoscelism is relatively rare.

Minimum Lethal Exposure

    A) SUMMARY
    1) A toxic dose has not been established.
    2) While a single bite can cause systemic loxoscelism, it is estimated that less than 15% of brown recluse bites result in significant effects (eg, significant scarring, chronic skin lesions, hospitalization) and systemic loxoscelism is relatively rare (Wendell, 2003).

Maximum Tolerated Exposure

    A) CASE REPORTS
    1) SYSTEMIC LOXOSCELISM
    a) CASE REPORT: A 6-year-old boy developed massive hemolysis, disseminated intravascular coagulopathy, shock (BP 77/47 mm Hg) and acute renal failure after a suspected loxoscelism envenomation. The patient was initially admitted with a one day history of abdominal pain, nausea, vomiting and intermittent fever following a presumed spider bite; a dead spider was found by the mother in the child's bed (Note: there is no report that the spider was identified at home or brought to the hospital for identification). He had erythroderma and 2 large, bullous lesions with ecchymotic and erythematous bases on his lower abdomen. His initial laboratory studies were significant for an elevated WBC and coagulation abnormalities (ie, prothrombin time 30.1; partial thromboplastin time 65.6; and INR 2.96) and dark urine that was positive for hemoglobin and myoglobin. The patient required immediate intubation with fluid resuscitation and red blood cell transfusion. The patient required dopamine and epinephrine for ongoing hypotension. Further laboratory analysis was not possible due to massive hemolysis. Due to the presence of anuria, metabolic acidosis, hyperkalemia, and ongoing need for blood products, the patient was started on plasma exchange therapy for hemolyzed plasma and continuous venovenous hemodiafiltration (CVVH). Over the next few weeks, the child gradually improved. By day 8, he was weaned off all inotropes and his neurologic function was normal. Hemolysis slowly resolved and PEX was discontinued on day 9 and CVVH was gradually weaned as his urine output increased. CVVH was discontinued on day 11 and the following day he was successfully extubated. He was discharged to home on day 28 with maintenance amlodipine therapy and no permanent sequelae (Said et al, 2014).
    b) CASE REPORTS: Systemic loxoscelism developed in 2 children that lived in North Carolina (a nonendemic region for brown recluse spiders). In the first case, a 12-year-old girl was admitted 18 hours after a suspected spider bite with fever, malaise, nausea, vomiting and anxiety. Her physical exam revealed a 3 cm x 3 cm area on the shoulder with a blanched center, yellow and blue discoloration, and faint erythema. She was treated for pain and released 18 hours later. Four days after exposure, she was readmitted with fever, malaise, a generalized scarlitiniform rash over the trunk and extremities and an increased bilirubin (2.4 mg/dL). By day 6, she was tachycardic with a widened pulse pressure and required oxygen therapy. Laboratory studies were consistent with an active hemolytic process and she was treated with blood products and gradually improved. The spider was later identified as a brown recluse (Loxosceles reclusa) by an entomologist. In the second case, a 9-year-old girl was seen in the ED for a painful lesion on her arm thought to be due to a spider bite. She was treated and released. By day 6, she was seen in a pediatrician's office appearing ill with a diffuse red rash and an erythematous, indurated lesion on her arm. She was immediately transferred to an ED. Upon arrival she was somnolent, hypotensive, and in respiratory distress requiring immediate intubation and ventilation and vasopressors. Her laboratory studies detected leukocytosis, severe anemia and acute hemolysis. Treatment included multiple transfusions, IV methylprednisolone and broad-spectrum antibiotics. Therapy also included surgical debridement of a necrotic lesion on her arm. She improved over the next several days. An entomologist confirmed the presence of 4 dead female recluse spiders in the home, however, their actual identity could not be confirmed because of their physical (ie, dried out) state (Zimmerman et al, 2014).

Toxicologic Mechanism

    A) The venom of Loxosceles species is composed of a number of proteins, enzymes, and nonenzymatic polypeptides, several of which have been isolated and studied in cell and tissue preparations. Purified brown recluse venom contains a 32,000 dalton protein with sphingomyelinase activity (Yarbrough, 1987). Currently, these mechanisms appear to be molecularly complex and may be dependent on many different toxins (Veiga et al, 2001).
    B) It is difficult, however, to relate the individual venom components to the severity of the clinical picture. In addition, the amounts of these components in themselves appear insufficient to account for the clinical syndrome.
    C) It would appear that component synergism may play a part in the overall tissue response, but perhaps more important is the autopharmacological reaction (the response of host cells to the presence of a complement-mediating foreign substance).
    1) DERMAL NECROSIS/SYSTEMIC EFFECTS - In a guinea pig model, pretreatment with a specific C-3 complement inhibitor prevented death in animals injected with twice the LD50 of the L. reclusa venom fraction responsible for dermal necrosis and systemic effects (Rees et al, 1982).
    a) Polymorphonuclear leukocytes also appear to play a role in the development of cutaneous loxoscelism (i.e., skin necrosis). Loxosceles venom has been shown to be a potent inducer of multiple inflammatory mediating chemokines in endothelial cell cultures (Gomez et al, 1997).
    b) In rabbits, pretreatment with nitrogen mustard delayed and reduced the development of edema and necrosis and prevented the development of subcutaneous hemorrhage following intradermal L. reclusa venom injection (Smith & Micks, 1970).
    2) COAGULOPATHIES - Venom toxins may act as proteases upon molecular constituents of plasma extracellular matrix (i.e., fibronection and fibrinogen) and basement membrane constituents (i.e., entactin and heparan sulfate proteoglycan). Its postulated that all of these degrading activities are responsible for producing hemorrhage, delayed wound healing and renal failure, as well as, the spreading of other noxious toxins (i.e., dermonecrotic protein). By disrupting the subendothelial basement membrane, blood vessel wall instability and increased permeability can occur (Veiga et al, 2001).
    3) NEPHROTOXICITY- In a mouse model, the venom of Loxosceles intermedia was found to cause light and electron microscopic evidence of renal damage as well as increased serum urea concentrations without causing hemolysis (Luciano et al, 2004). Researchers were able to identify a 30 kiloDalton toxin that bound to renal tissue in venom treated mice.

General Bibliography

    1) Alario A, Price G, & Stahl R: Cutaneous necrosis following a spider bite: a case report and review. Pediatrics 1987; 79:618-621.
    2) Andersen RJ, Campoli J, Johar SK, et al: Suspected brown recluse envenomation: A case report and review of different treatment modalities. J Emerg Med 2010; Epub:Epub.
    3) Anderson EJ: Recognizing the recluse spider bite in children: necrotic arachnidism. J Louisiana State Med Soc 1987; 139:33-36.
    4) Anderson PC: Necrotizing spider bites. Am Fam Phy Pract Therapeu 1982; 26:198-203.
    5) Anderson PC: Necrotizing spider bites. Am Fam Physician 1982a; 26:198-203.
    6) Auer AI & Hershey FB: Surgery for necrotic bites of the brown spider. Arch Surg 1974; 108:612-618.
    7) Baldwin GA, Smith DF, & Fike SD: Loxoscelism in Canada. CMAJ 1988; 138:521-522.
    8) Barbaro KC, Cardoso JLC, & Eickstedt VRD: IgG antibodies to loxosceles spider venom in human envenoming. Toxicon 1992; 30:1117-1121.
    9) Barrett SM, Romine-Jenkins M, & Blick KE: Passive hemagglutination inhibition test for diagnosis of brown recluse spider bite envenomation. Clin Chem 1993; 39:2104-2107.
    10) Barrett SM: Dapsone or electric shock therapy of brown recluse spider envenomation?. Ann Emerg Med 1994; 24:21-25.
    11) Berger RS: A critical look at therapy for the brown recluse spider bite. Arch Dermatol 1973a; 107:298.
    12) Berger RS: The unremarkable brown recluse bite. JAMA 1973; 225:1109-1111.
    13) Bernstein B & Ehrlich F: Brown recluse spider bites. J Emerg Med 1986; 4:457-462.
    14) Bilgili SG, Karadag AS, Karadag R, et al: A case of Spider bite localized to the eyelid. Cutan Ocul Toxicol 2013; 32(1):83-85.
    15) Bradley JG & Starkey DJ: Necrotic spider bites in Kansas. Kansas Med 1988; 89:166-168.
    16) Butz WC: Envenomation by the brown recluse spider (aranae, scytodidae) and related species. A public health problem in the United States. Clin Toxicol 1971; 4:515-524.
    17) Cacy J & Mold JW: The clinical characteristics of brown recluse spider bites treated by family physicians - an OKPRN study. J Fam Prac 1999; 48:536-542.
    18) Cardoso JLC, Hui Wen F, & Franca FOS: Detection by enzyme immunoassay of loxosceles gaucho enom in necrotic skin lesions caused by spider bites in Brazil. Trans Roy Soc Trop Med Hyg 1990; 84:608-609.
    19) Chan S: Recurrent necrotising arachnidism [letter]. Med J Aust 1998; 169:642-643.
    20) Chu JY, Rush CT, & O'Connor DM: Hemolytic anemia following brown spider (Loxosceles reclusa) bite. Clin Toxicol 1978; 12:531-534.
    21) DeLozier JB, Reaves L, & King LE Jr: Brown recluse spider bites of the upper extremity. Southern Med J 1988; 81:181-184.
    22) Denny WF, Dillaha J, & Morgan PN: Hemolytic effect of Loxosceles reclusus venom: In vivo and in vitro studies. J Lab Clin Med 1964; 64:291-298.
    23) Diaz JH: The global epidemiology, syndromic classification, management, and prevention of spider bites. Am J Trop Med Hyg 2004; 71(2):239-250.
    24) Donepudi SK, Ahmed KA, Stocks RS, et al: Aural involvement in loxoscelism: case report and literature review. Int J Pediatr Otorhinolaryngol 2005; 69(11):1559-1561.
    25) Edwards JJ, Anderson RL, & Wood JR: Loxoscelism of the eyelids. Arch Ophthalmol 1980; 98:1997-2000.
    26) Efrati P: Bites by loxosceles spiders in Israel. Toxicon 1969; 6:239-241.
    27) Eichner ER: Spider bite hemolytic anemia: positive coombs' test, erythrophagocytosis, and leukoerythroblastic smear. Am J Clin Pathol 1984; 81:683-687.
    28) Ellenhorn MJ & Barceloux DG: Medical Toxicology, Diagnosis and Treatment of Human Poisoning, Elsevier, New York, NY, 1988.
    29) Farah R, Shay M, & Bitterman O: Hand-foot syndrome caused by brown spider bite. Acta Derm Venereol 2006; 86(4):361-362.
    30) Fardon DW, Wingo CW, & Robinson DW: The treatment of brown spider bite. Plast Reconstr Surg 1967; 40:482-488.
    31) Fisher RG, Kelly P, & Krober MS: Necrotic arachnidism. WJM 1994; 160:570-571.
    32) Futrell JM: Loxoscelism. Am J Med Sci 1992; 304:261-267.
    33) Gendron BP: Loxosceles reclusa envenomation. Am J Emerg Med 1990; 8:51-54.
    34) Gomez HF, Miller M, & Desai A: Loxosceles venom induces endothelial cell production of multiple major chemokines by endothelial cells (abstract). J Toxicol - Clin Toxicol 1997; 35:557.
    35) Gomez HF, Miller MJ, & Trachy JW: Intradermal anti-loxosceles fab fragments attenuate dermonecrotic arachnidism. Acad Emerg Med 1999; 6:1195-1202.
    36) Gorham JR & Rheney TB: Envenomation by ths spiders Chiracanthium inclusum and Argiope aurantia. JAMA 1968; 206:1958-1962.
    37) Gorham JR: The geographic distribution of the brown recluse spider, loxosceles reclusa (Araneae, Scytodidae) and related species in the United States. US Dept Agr Coop Econ Ins Rpt 1968; 18:171-175.
    38) Goto CS, Abramo TJ, & Ginsburg CM: Upper airway obstruction caused by brown recluse spider envenomization of the neck. Am J Emerg Med 1996; 14:660-662.
    39) Gross AS, Wilson DC, & King LE Jr: Persistent segmental cutaneous anesthesia after a brown recluse spider bite. South Med J 1990; 83:1321-1323.
    40) Grothaus RH & Teller LW: Envenomization by the spider Lycosa miami Wallace. J Med Entomol 1968; 5:500.
    41) Hansen RC & Russell FE: Dapsone use for Loxosceles envenomation treatment (letter). Vet Hum Toxicol 1984; 26:260.
    42) Hardman JT, Beck ML, & Hardman PK: Incompatibility associated with the bite of a brown recluse spider (Loxosceles reclusa). Transfusion 1983; 23:233-236.
    43) Hobbs G, Anderson A, & Greene T: Comparison of hyperbaric oxygen and dapsone therapy for Loxosceles envenomation. Acad Emerg Med 1996; 3:758-761.
    44) Holtslag I, van Wijk M, & Kon M: Partial ear necrosis due to recluse spider bite. J Plast Reconstr Aesthet Surg 2014; 67(3):419-421.
    45) Hoover EL, Williams W, & Koger L: Pseudoepitheliomatous hyperplasia and pyoderma gangrenosum after a brown recluse spider bite. South Med J 1990; 83:243-246.
    46) Hunt G: Treatment of choice for brown recluse spider bites (letter). 1976; 5:619-620.
    47) Ingber A, Trattner A, & Cleper R: Morbidity of brown recluse spider bites. Acta Derm Venereal 1991; 71:337-340.
    48) Iserson KV: Methemoglobinemia from dapsone therapy for a suspected brown spider bite. J Emerg Med 1985; 3:285-288.
    49) King LE & Rees RS: Dapsone treatment of a brown recluse bite. JAMA 1983; 250:648.
    50) King LE & Rees RS: Management of brown recluse spider bite. JAMA 1984; 251:889-890.
    51) Krmaer N & Rosenstein ED: Lyme disease misdiagnosed as a brown recluse spider bite (letter). Ann Intern Med 1987; 107:782.
    52) Kunkel DB: The toxic emergency. Emerg Med 1985; 17:124-128.
    53) Lessenden CM & Zimmer LK: Brown spider bites. J Kansas Med Soc 1960; 61:379-385.
    54) Lewis MI & Regan JF: Necrotic Arachnidism. California Med 1966; 105:457-462.
    55) Longfield RN: Cheiralgia paresthetica after necrotic arachnidism (letter). Arch Neurol 1981; 38:470.
    56) Lowry BP, Bradfield JF, & Carroll RG: A controlled trial of topical nitroglycerin in a new zealand white rabbit model of brown recluse spider envenomation. Ann Emerg Med 2001; 37:161-165.
    57) Luciano MN, da Silva PH, Chaim OM, et al: Experimental evidence for a direct cytotoxicity of Loxosceles intermedia (brown spider) venom in renal tissue.. J Histochem Cytochem 2004; 52:455-467.
    58) Madrigal GC, Ercolani RLK, & JEW: Toxicity from a bite of the brown spider (loxosceles reclusus). Clin Pediatr 1972; 11:641-644.
    59) Majeski JA & Durst GG: Necrotic arachnidism. South Med J 1976; 69:887-891.
    60) Masters EJ: Loxoscelism. Images in Clinical Medicine 1998; 339:379.
    61) Maynor ML, Abt JL, & Osborne PD: Brown recluse spider bites: beneficial effects of hyperbaric oxygen. J Hyperbaric Med 1992; 7:89-102.
    62) Miller MJ, Gomez HF, & Snider RJ: Detection of loxosceles venom in lesional hair shafts and skin: Application of a specific immunoassay to identiry dermonecrotic arachnidism. Am J Emerg Med 2000; 18:626-628.
    63) Minton SA Jr & Olson C: A case of spider bite with severe hemolytic reaction. Pediatrics 1964; 33:283-284.
    64) Newlands G & Atkinson P: Behavioural and epidemiological considerations pertaining to necrotic araneism in souther Africa. S Afr Med J 1990; 77:92-95.
    65) Newlands G & Atkinson P: Review of southern African spiders of medical importance, with notes on the signs and symptoms of envenomation. S Afr Med J 1988; 73:235-239.
    66) Nicholson JF & Nicholson BH: Hemolytic anemia from brown spider bite. Oklahoma State Med Assoc 1962; 55:234-236.
    67) Pauli I, Puka J, Gubert IC, et al: The efficacy of antivenom in loxoscelism treatment. Toxicon 2006; 48(2):123-137.
    68) Phillips S, Kohn M, & Baker D: Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann Emerg Med 1995; 25:363-368.
    69) Pincus SJ, Winkel KD, Hawdon GM, et al: Acute and recurrent skin ulceration after spider bite. Med J Aust 1999; 171:99-102.
    70) Rauber A: An unusual case of loxoscelism. Vet Hum Toxicol 1983; 25(Suppl 1):43-44.
    71) Redman JF: Human envenomation by a Lycosid. Arch Dermatol 1974; 110:111-112.
    72) Rees R, Campbell D, & Rieger E: The diagnosis and treatment of brown recluse spider bites. Ann Emerg Med 1987; 16:945-949.
    73) Rees R, Shack RB, & Withers E: Management of the brown recluse spider bite. Plastic Reconstruct Surg 1981; 68:768-773.
    74) Rees RS, Altenbern PD, & Lynch JB: A comparison of early surgical excision versus dapsone and delayed surgical excision. Ann Surg 1985; 202:659-663.
    75) Riley HD Jr, McLean WR, & Start AH: Brown spider bite with severe hemolytic phenomena. Oklahoma State Med Assoc 1964; 57:218-223.
    76) Russell FE & Gertsch WJ: Arthropod bites. Toxicon 1983; 21:337-339.
    77) Russell FE, Waldron WG, & Madon MB: Bites by the brown spiders Loxosceles unicolor and Loxosceles arizonica in California and Arizona. Toxicon 1969; 7:109-117.
    78) Russell FE: Venomous arthropods. Vet Hum Toxicol 1991; 33:505-508.
    79) Said A, Hmiel P, Goldsmith M, et al: Successful use of plasma exchange for profound hemolysis in a child with loxoscelism. Pediatrics 2014; 134(5):e1464-e1467.
    80) Sams HH, Hearth SB, & Long LL: Nineteen documented cases of Loxosceles reclusa envenomation. J Am Acad Dermatol 2001; 44:603-608.
    81) Schenone H & Prats F: Arachnidism by loxosceles laeta. Arch Dermatol 1961; 83:139-142.
    82) Seifert SA, Boyer LV, & Murphy M: Loxosceles arizonica envenomation with rhabdomyolysis (abstract). J Toxicol - Clin Toxicol 2000; 38:510.
    83) Smith CW & Micks DW: The role of polymorphonuclear leukocytes in the lesion caused by the venom of the brown spider, loxosceles reclusa. Lab Invest 1970; 22:90-93.
    84) Stoecker WV, Green JA, & Gomez HF: Diagnosis of loxoscelism in a child confirmed with an enzyme-linked immunosorbent assay and noninvasive tissue sampling. J Am Acad Dermatol 2006; 55(5):888-890.
    85) Strain GM, Snider TG, & Tedford BL: Hyperbaric oxygen effects on brown recluse spider (Loxosceles Reclusa) envenomation in rabbits. Toxicon 1991; 29:989-996.
    86) Svendsen FJ: Treatment of clinically diagnosed brown recluse spider bites with hyperbaric oxygen: a clinical observation. J Arkansas Med Soc 1986; 83:199-204.
    87) Swanson DL & Vetter RS: Bites of brown recluse spiders and suspected necrotic arachnidism. N Engl J Med 2005; 352(7):700-707.
    88) Taylor EH & Denny WF: Hemolysis, renal failure and death, presumed secondary to bite of brown recluse spider. South Med J 1966; 59:1209-121.
    89) Traub SJ, Hoffman RS, & Nelson LS: Pharyngeal irritation after eating cooked tarantula (abstract). J Toxicol - Clin Toxicol 2001; 39:562.
    90) Veiga SS, Zanetti VC, & Braz A: Extracellular matrix molecules as targets for brown spider venom toxins. Braz J Med Biol Res 2001; 34:843-850.
    91) Vest DK: Necrotic arachnidism in the northwest United States and its probable relationship to tegenaria agrestis (Walckenaer) spiders. Toxicon 1987; 25:175-184.
    92) Vorse H, Seccareccio P, & Woodruff K: Disseminated intravascular coagulopathy following fatal brown spider bite (necrotic arachnidism). J Pediatr 1972; 80:1035-1037.
    93) Wand M: Necrotic arachnidism: a new entity in the northwest. NW Med 1972; 71:292-295.
    94) Wasserman GS & Anderson PC: Loxoscelism and necrotic arachnidism. J Tox Clin Toxicol 1984; 21:451-472.
    95) Wasserman GS: Wound care of spider and snake envenomations. Ann Emerg Med 1988; 17:1331-1335.
    96) Way S, Lachar G, & Givens M: A child with fever, malaise, and a skin wound. Pediatr Emerg Care 2005; 21(9):620-623.
    97) Wendell RP: Brown recluse spiders: a review to help guide physicians in nonendemic areas. South Med J 2003; 96(5):486-490.
    98) Wesley RE, Ballinger WH, & Close LW: Dapsone in the treatment of presumed brown recluse spider bite of the eyelid. Ophthalmic Surg 1985; 16:116-120.
    99) Wille RC & Morrow JD: Case Report: dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider. Am J Med Sci 1988; 296:270-271.
    100) Willis GA: Loxoscelism in Canada. CMAJ 1988; 139:11-12.
    101) Wong RC, Hughes SE, & Voorees JJ: Sider bites. Arch Dermatol 1987; 123:98-104.
    102) Wright SW, Wrenn KD, & Murray L: Clinical presentation and outcome of brown recluse spider bite. Ann Emerg Med 1997; 30:28-32.
    103) Yarbrough BE: Current treatment of brown recluse spider bites. Curr Concepts Wound Care 1987; Winter:4-6.
    104) Zambrano A, Gonzalez J, & Callejas G: [Severe loxoscelism with lethal outcome. Report of one case]. Rev Med Chil 2005; 133(2):219-223.
    105) Zimmerman SP, Rothman JA, Hansen JL, et al: Systemic loxoscelism in a nonendemic area: a diagnostic challenge for the unsuspecting physician. Clin Pediatr (Phila) 2014; 53(11):1098-1100.